Table 6 Hazard ratios (HRs) of clinical KOA associated with serum lipids levels in the cohort analysis (N = 9062), 2008–2013.

From: The cross-sectional and longitudinal effect of hyperlipidemia on knee osteoarthritis: Results from the Dongfeng-Tongji cohort in China

Variables

HRs increase per 1-unit increase in serum lipids levels

HRs for the levels of serum lipids versus the normal group

Group 1

Group 2

Group 3: With hyperlipidemia and use of lipid-lowering drugs

Group 4: Without hyperlipidemia but taking lipid-lowering drugs for prevention of other diseases

TC

1.04(0.94–1.16)

Reference

0.95(0.75–1.20)

1.53(1.14–2.04)*

1.30(0.61–2.77)

TG

1.05(1.01–1.10)*

Reference

1.05(0.79–1.38)

1.58(1.20–2.09)*

1.34(0.63–2.86)

LDL-C

1.00(0.90–1.17)

Reference

1.10(0.86–1.41)

1.61(1.21–2.14)*

1.37(0.64–2.92)

HDL-C

1.01(0.75–1.36)

Reference

0.93(0.65–1.34)

1.55(1.18–2.04)*

1.32(0.62–2.80)

  1. TC: total cholesterol. TG: triglyceride. LDL-C: low density lipoprotein cholesterol. HDL-C: high density lipoprotein cholesterol.
  2. TC: group 1, <5.18 mmol/L and without lipid-lowering drugs; group 2, ≥5.18 mmol/L and without lipid-lowering drugs.
  3. TG: group 1, <1.70 mmol/L and without lipid-lowering drugs; group 2, ≥1.70 mmol/L and without lipid-lowering drugs.
  4. LDL-C: group 1, <3.37 mmol/L and without lipid-lowering drugs; group 2, ≥3.37 mmol/L and without lipid-lowering drugs.
  5. HDL-C: group 1, ≥1.04 mmol/L and without lipid-lowering drugs; group 2, <1.04 mmol/L and without lipid-lowering drugs.
  6. Adjusted for age (as a continuous variable), WHR (as a continuous variable), and gender. *p-value < 0.05.
Back to article page